ArticleAntimicrobial agents and chemotherapy2015
Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 32 citations in OpenAlex.
- The role of Tat in HIV latency and reactivation.Frontiers in immunology · 2025Review
- Sodium lignosulfonate inhibits multiple virulent proteins of human fungal pathogen Candida albicans.Archives of microbiology · 2024Article
- Changes to the Simian Immunodeficiency Virus (SIV) Reservoir and Enhanced SIV-Specific Responses in a Rhesus Macaque Model of Functional Cure after Serial Rounds of Romidepsin Administrations.Journal of virology · 2022Article
- So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.Viruses · 2022Review
- Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection.Disease markers · 2022Review
- Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapy.The Journal of clinical investigation · 2021Article
- Oral Vaccination Approaches for Anti-SHIV Immunity.Frontiers in immunology · 2021Article
- Advances in Developing CAR T-Cell Therapy for HIV Cure.Frontiers in immunology · 2020Review
- Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques.Frontiers in immunology · 2020Article
- The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections.Cell host & microbe · 2019Article
- Clonal expansion of SIV-infected cells in macaques on antiretroviral therapy is similar to that of HIV-infected cells in humans.PLoS pathogens · 2019Article
- TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremia.JCI insight · 2019Article
- Nanotechnology approaches to eradicating HIV reservoirs.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2019Review
- Ultrasensitive Immunoassay for Simian Immunodeficiency Virus p27AIDS research and human retroviruses · 2018Article
- Wake me up before you go: a strategy to reduce the latent HIV reservoir.AIDS (London, England) · 2018Article
- Defining total-body AIDS-virus burden with implications for curative strategies.Nature medicine · 2017Article
- Eradication of HIV-1 latent reservoirs through therapeutic vaccination.AIDS research and therapy · 2017Review
- Tackling HIV and AIDS: contributions by non-human primate models.Lab animal · 2017Article
- Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy.PLoS pathogens · 2017Article
- In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies.The Journal of infectious diseases · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 1 country.
Funding
Abstract
Replication-competent human immunodeficiency virus (HIV) persists in infected people despite suppressive combination antiretroviral therapy (cART), and it represents a major obstacle to HIV functional cure or eradication. We have developed a model of cART-mediated viral suppression in simian human immunodeficiency virus (SIV) mac239-infected Indian rhesus macaques and evaluated the impact of the histone deacetylase inhibitor (HDACi) romidepsin (RMD) on viremia in vivo. Eight macaques virologically suppressed to clinically relevant levels (<30 viral RNA copies/ml of plasma), using a three-class five-drug cART regimen, received multiple intravenous infusions of either RMD (n = 5) or saline (n = 3) starting 31 to 54 weeks after cART initiation. In vivo RMD treatment resulted in significant transient increases in acetylated histone levels in CD4(+) T cells. RMD-treated animals demonstrated plasma viral load measurements for each 2-week treatment cycle that were significantly higher than those in saline control-treated animals during periods of treatment, suggestive of RMD-induced viral reactivation. However, plasma virus rebound was indistinguishable between RMD-treated and control-treated animals for a subset of animals released from cART. These findings suggest that HDACi drugs, such as RMD, can reactivate residual virus in the presence of suppressive antiviral therapy and may be a valuable component of a comprehensive HIV functional cure/eradication strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.